Status:
COMPLETED
Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Healthy
Eligibility:
All Genders
3+ years
Phase:
PHASE3
Brief Summary
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparab...
Eligibility Criteria
Inclusion
- signed and dated informed consent
- being healthy
- mental health enough to understand the study, the informed consent form and the questionnaire
Exclusion
- known to be allergic to constituents of the vaccine
- having an autoimmune disorder, taking immunomodulating drugs or having immune disfunction secondary to HIV
- having had a documented serious adverse reaction to previous influenza vaccination
- having had documented influenza infection or vaccination in the six months prior to the start of the study
- having received any other vaccines, immunoglobulins or investigational drugs in the month prior to the start of the study
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT00325260
Start Date
March 1 2006
Last Update
November 1 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 1
Nanjing, China